NEW YORK (GenomeWeb News) – MDxHealth and Bostwick Laboratories today announced a marketing agreement covering MDxHealth's ConfirmMDx prostate cancer test.
NEW YORK (GenomeWeb News) – MDx Health and HistoGeneX today announced a collaboration to provide molecular diagnostic testing services to drug manufacturers and oncologists.
NEW YORK (GenomeWeb News) – MDxHealth today announced New York has certified the company's prostate cancer test, allowing MDxHealth to offer the test to residents in the state.
MDxHealth and GlaxoSmithKline Biologicals, both of Belgium, have been awarded US Patent No. 8,481,700, "Detection of MAGE-A expression."
Ilse Vlassenbroeck and Katja Bierau are named as inventors.
MDxHealth Gains Access to Japanese Pharmas Interested in Personalized Rx Development
NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed a partnership with a subsidiary of Sumitomo to bring the firm's molecular diagnostics products to the Japanese market.
NEW YORK (GenomeWeb News) – MDxHealth today said that it has raised €18 million ($23.6 million) through a private placement of new shares.
This story has been updated with additional information on MDxHealth's MGMT glioblastoma test.
NEW YORK (GenomeWeb News) – MDxHealth today reported a roughly 53 percent increase in its first-quarter revenues year over year driven by sales of its prostate cancer molecular test.
NEW YORK (GenomeWeb News) – MDxHealth today said that it has received ISO 9001:2008 certification of its Irvine, Calif.-based laboratory.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.